Structural basis for agonism and antagonism for a set of chemically related progesterone receptor modulators by Lusher, S.J. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/92379
 
 
 
Please be advised that this information was generated on 2017-12-06 and may be subject to
change.
Structural Basis for Agonism and Antagonism for a Set of
Chemically Related Progesterone Receptor Modulators
Received for publication, June 16, 2011, and in revised form, August 3, 2011 Published, JBC Papers in Press, August 17, 2011, DOI 10.1074/jbc.M111.273029
Scott J. Lusher‡1, Hans C. A. Raaijmakers‡, Diep Vu-Pham§, Koen Dechering§, TsangWai Lam§, Angus R. Brown¶,
Niall M. Hamilton¶, Olaf Nimz¶, Rolien Bosch‡, Ross McGuire‡, Arthur Oubrie‡, and Jacob de Vlieg‡
From the Departments of ‡Molecular Design and Informatics and §Molecular Pharmacology, DMPK, MSD, P. O. Box 20,
5340 BHOss, The Netherlands, the ¶Department of Chemistry, MSD, NewhouseML1 5SH, United Kingdom, and the
Computational Drug Discovery Group, Radboud University, Nijmegen 6525 HP, The Netherlands
The progesterone receptor is able to bind to a large number
and variety of ligands that elicit a broad range of transcriptional
responses ranging from full agonism to full antagonism and
numerous mixed profiles inbetween.We describe here two new
progesterone receptor ligand binding domain x-ray structures
bound to compounds from a structurally related but function-
ally divergent series, which show different binding modes cor-
responding to their agonistic or antagonistic nature. In addi-
tion, we present a third progesterone receptor ligand binding
domain dimer bound to an agonist inmonomer A and an antag-
onist inmonomer B, which display bindingmodes in agreement
with the earlier observation that agonists and antagonists from
this series adopt different binding modes.
The progesterone receptor (PR)2 is a nuclear receptor,
related most closely to the glucocorticoid receptor, androgen
receptor, and mineralocorticoid receptor (1). PR has a primary
role in pregnancy, both the initiation and maintenance of ges-
tation (2), as well as other functions related to menstruation
and the endometrium (3). PR drug discovery has historically
focused on three areas as follows: the discovery of pure agonists
for contraception, discovery of anti-progestins blocking the
function of endogenous progesterone for pregnancy termina-
tion, and more recently, the development of so-called selective
progesterone receptor modulators (SPRMs) for a number of
indications, including uterine fibroids and endometriosis (2).
PR modulators continue to provide important medical inter-
ventions in a number of areas of reproductive medicine (4, 5)
with an outlook for application in other fields, including oncol-
ogy (6). Clinically relevant PR modulators span a spectrum of
function from full agonists through to full antagonists (7), with
interest growing particularly in the development of compounds
with mixed profiles (8, 9). The most comprehensively studied
SPRMs are all steroidal, including compounds such as asopris-
nil (10), but early accounts of nonsteroidal SPRMs have been
reported as well (11, 12).
Identifying the molecular determinants for the ligand-in-
duced switch between agonism and antagonism, and the infi-
nite number of mixed profiles between, is an important step in
enabling rational design of novel SPRMs and is facilitated by
structural biology studies of the progesterone receptor (13).
Nuclear hormone receptor structural biology has proven to be
important in helping to understand the biology and function of
this protein family, including ligand-driven effects (14–19).
X-ray crystallography studies of PR bound to the 11-substi-
tuted steroids, asoprisnil (20) and RU486 (21), along with the
full PR agonist levonorgestrel (22) clearly indicate a crucial
function for Met909 in the agonism/antagonism balance. This
has also been shown to be true for nonsteroidal SPRMs (11, 12).
Met909 sits within helix-12 at the C-terminal end of the ligand
binding domain (LBD), and in the classic agonist conformation
of the receptor, is oriented toward the ligand binding pocket.
Met909 is typically the only helix-12 residue directly in contact
with ligands, and the nature of these interactions appears to be
a key determinant of the function of the receptors. Clashes
between Met909 and ligands are likely to destabilize helix-12
(21), which results in a reduced agonistic response. It has even
been suggested that the degree of clash with Met909 might cor-
respond directly to the reduction in agonism (2), but this has yet
to be shown categorically.
Our earlier work on the discovery and optimization of a
selective nonsteroidal glucocorticoid receptor antagonist (23)
resulted in the synthesis of a number of moderately active PR
modulators, including OrgA, OrgB, and OrgC (see Table 1).
Interestingly,OrgA is a partial PR agonist despite high chemical
similarity to OrgB and OrgC, which are both full PR antago-
nists. Furthermore, earlier descriptions of nonsteroidal PR
antagonists tended to include mimics of the dimethylaniline
moiety of RU486 (24), but neither OrgB nor OrgC has a likely
replacement for this group.
To investigate the molecular basis for antagonism in OrgB
and OrgC and the lack of antagonism in OrgA, we have deter-
mined their x-ray crystal structures in complexwith the agonist
conformation of PR following a previously described soaking
method (21). Comparison of these structures, alongwith earlier
structures of PR bound to norethindrone and RU486, indicate a
basis for the antagonism ofOrgB andOrgC, with a clear role for
Met909. We also show that OrgA adopts a remarkably different
binding mode to the other compounds from the series explain-
ing its lack of antagonism.
The atomic coordinates and structure factors (codes 3ZR7, 3ZRA, and 3ZRB)
have been deposited in the Protein Data Bank, Research Collaboratory for
Structural Bioinformatics, Rutgers University, New Brunswick, NJ
(http://www.rcsb.org/).
1 To whom correspondence should be addressed. Tel.: 31412663938; E-mail:
scott.lusher@merck.com.
2 The abbreviations used are: PR, progesterone receptor; LBD, ligand binding
domain; SPRM, selective progesterone receptor modulator.
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MATERIALS ANDMETHODS
Expression andPurification of PRLBD—ThePRLBD, includ-
ing residues 678–933, was cloned in pET15b (Novagen).
Expression was performed in Escherichia coli BL21 Star (DE3)
(Invitrogen) in 2 YTmedium by overnight induction at 20 °C
in the presence of 10 M OrgA. Bacteria were lysed in buffer A
(50mMTris, pH 7.8, 250mMNaCl, 10% glycerol, 10mM-mer-
captoethanol) with 0.4 mM Pefabloc (Roche Applied Science)
and 50 M OrgA and purified on nickel-nitrilotriacetic acid.
Fractions were eluted with buffer A with 100 mM imidazole.
Elution fractions were collected and treated with 2.5% w/w
thrombin (Kordia) overnight at 4 °C to cleave the N-terminal
His tag. Thrombin was removed by adding benzamidine-Sep-
harose (GE Healthcare), centrifuging for 10 min at 5000  g,
and harvesting the supernatant. To make the final crystalliza-
tion sample, the protein was dialyzed to buffer A to which 1mM
EDTA, 1 mM dithiothreitol, and 10 M OrgA were added and
subsequently concentrated in a stirring cell to about 4mg/ml as
measured by its absorption at 280 nm.The samplewas stored at
70 °C in aliquots of 50 l.
Crystallization—Crystals of the PR LBD in complex with
OrgA were grown at room temperature from 3.5-l drops
hanging over a mother liquor of 20–30% polyethylene glycol
3350, 0.1 M Hepes, pH 6.5, 100 mM Mg2SO4, and 10% glycerol.
Drops consisted of 2 l of protein sample and 1 l of mother
liquor and 0.5 l of 40% 1,3-propanediol. Crystals usually
appeared after about 3 days and were kite-shaped. One crystal
was transferred to a cryoprotectant solution of 80% mother
liquor and 20% glycerol, dipped in liquid nitrogen, and shipped
for data collection to 1.65 Å at 100 K.
Ligand Replacement—Additional crystals of the PR LBD in
complex with OrgA were collected and transferred to mother
liquor to which 0.25 mM of either compound OrgB or OrgC
were added. 0.25mM is a significant excess of either compound.
The crystals were stored in a sitting drop at room temperature.
The solutions surrounding the crystals were replaced by fresh
solution 10 times over a period of 2 weeks. After this period, the
crystals were frozen as described above and shipped for data
collection. The dataset for OrgB complex was collected to 2.0 Å
at 100 K, and the data for OrgC complex was collected to 1.8 Å
at 100 K.
DataCollection—All datawere collected by theMXpress ser-
vice of the European Synchrotron Radiation Facility, Grenoble,
France. Structures were solved and refined using the CCP4i
interface of the CCP4 software suite (25). All figures have been
generated using PyMOL (PyMOL molecular graphics system,
Schrodinger, LLC). Data are summarized in Table 2.
Cell-based Activity Measurements—PR agonist and antago-
nist data for OrgA, OrgB, OrgC, and the reference compounds
progesterone and RU486 have beenmeasured following proce-
dures outlined in earlier publications (26–28). Agonism was
measured via PR-induced activation of a stably transfected
murine mammary tumor virus-luciferase reporter in Chinese
hamster ovary cells (27). Org 2058, a PR agonist, (29) was used
as a reference. Antagonism was determined by a decrease in
Org 2058-induced activation, by competition with the com-
pound of interest. Assays are run in a standardized fashion, and
results presented are the average of a duplicate test in two dif-
ferent experiments.
RESULTS ANDDISCUSSION
Agonism and AntagonismAre Not Consistent across Series— In
vitro agonism and antagonism of OrgA, OrgB, and OrgC has
been measured in cell-based assays alongside progesterone,
norethindrone, and RU486 as references with a summary of
results shown in Table 1. Fig. 1A shows the agonistic dose-
response curves for all six compounds with progesterone and
norethindrone displaying a full agonist effect comparedwith no
effect from RU486, OrgB, and OrgC. The reverse is seen in the
antagonistic assaywithRU486,OrgB, andOrgCdisplaying fully
antagonistic responses and norethindrone and progesterone
showing no effect. OrgA has the unique (among this set) profile
of showing a partial agonistic response in the agonistic setting
and no response in the antagonistic setting. The molecular
basis of the PR partial agonism of OrgA compared with the full
PR antagonism of OrgB and OrgC was not apparent, and their
x-ray structures were determined to explain the basis for the
differing functionality.
Structure of PR LBDDimer Complexed to OrgA—The overall
fold of the PR LBD homodimer bound to OrgA is identical to
the structure bound to norethindrone with an average root
mean square deviation of 0.21 Å for all equivalent C atoms. As
for the previously described PR x-ray structures bound to non-
steroidal ligands (12, 30, 31), OrgA binds within the traditional
ligand-binding pocket in a similar manner to reference steroids
TABLE 1
Cell-basedagonismandantagonism, shown forOrgA,OrgB, andOrgC
with data and structures for progesterone, norethindrone, and RU486
shown as references
Agonism and antagonism are shown as EC50 values (in nanomolar) with percentage
efficacies associated. Efficacy is measured by curve height at maximal effect and
expressed as percentage of reference compound effect. 1000 nM indicates no
response at the highest tested concentration.
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as shown in Fig. 2. Electron density maps around the ligand in
monomers A and B of the classic dimer are shown in Fig. 3, A
and B. The maps account for the entire ligand and enable pre-
cise positioning of the ligand with high confidence. Published
x-ray structures of PR bound to norethindrone (32) and RU486
(21) show direct interactions between the 3-keto groups from
each ligand to Gln725 and Arg766 as well as a structurally con-
served water molecule completing complex H-bonding net-
works as shown in Fig. 4, A and B. OrgA, as shown in Fig. 4C,
makes no direct H-bond to either Gln725 or Arg766 but rather
relies on water-mediated interactions to these two residues via
the previously described conserved water. This appears to be a
result of the nitrogen overlayingmore closelywith the carbon at
position 3 in the steroid than the carbonyl oxygen attached at
this position as seen in Fig. 2. Although this surely has an effect
on the strength of interaction with Gln725 and Arg766, it does
allow the methyl groups on the isoxazole to overlay well with
the steroid scaffold, specifically positions 2 and 6 (labeled in
Table 1). This may have benefits in terms of potency by maxi-
mizing hydrophobic van derWaals contacts between the ligand
and receptor. The implications of the modified interaction of
OrgA with Gln725 and Arg766 are discussed below.
OrgA makes a direct H-bond to Asn719 via its sulfonamide
nitrogen in contrast to norethindrone and RU486, which both
require the presence of a water molecule to mediate interac-
tions to this residue. Interaction with the equivalent residue in
the glucocorticoid receptor, Asn564, is a prerequisite for potent
FIGURE 1. Compound activities on PR-drivenmurinemammary tumor virus-luciferase reporter activity. Assays were run in an agonistic mode (A) or an
antagonistic mode (B). In the antagonistic mode, 0.1 nM Org 2058 was added to activate the reporter. Reporter activities are expressed relative to the activity
of a saturating concentration of Org 2058, which was set at 100%. The figure shows mean values and standard deviations from four replicate experiments.
FIGURE2.OverlayofOrgA (carbons coloredorange) comparedwithnore-
thindrone (carbons colored green) in A and RU486 in B (carbons colored
green). Protein-ligand complexes aligned using the Motif function in Yasara
(33) and images were generated using PyMOL.
TABLE 2
Final crystallographic data and refinement statistics
Data in parentheses indicate the last resolution shell. r.m.s.d. means root mean square deviation.
Structure PR-OrgA PR-OrgB PR-OrgC
Compound(s) OrgA OrgB OrgC & OrgA
Space group P21 P21 P21
Unit cell 57.79 64.24 69.98 Å3 56.305 64.114 69.932 Å3 56.25 64.06 69.69 Å3
-Angle 95.67° 96.53° 96.62°
Resolution 47.193 to 1.65 Å (1.74 to 1.65 Å) 28.12 to 1.9 Å (1.97 to 1.9 Å) 46.17 to 1.80 Å (1.9 to 1.8 Å)
Completeness 95.2% (63.1%) 97.4% (95.5%) 96.5% (95.8)
Rpima 0.038 (0.291) 0.067 (0.388) 0.042 (0.206)
Mn(I/) 14.4 (2.8) 9.3 (2.6) 12.9 (3.5)
Rfactor/Rfreeb 0.177/0.206 0.213/0.248 0.184/0.221
Atoms 4571 4206 4384
Protein atoms 4135 4062 4077
Ligand atoms 52 54 52
Water molecules 350 85 226
Other molecules (no. of atoms)
Glycerol 64 5 29
r.m.s.d. bonds Å 0.01 Å 0.01 Å 0.007 Å
r.m.s.d. angles 1.2° 1.128° 1.17°
B-factors (average Å2)
Main chain 5.4 20.7 12.2
Side chain 7.8 22.2 14.3
Water molecules 17.4 24.3 21
Ligand A-chain 12.3 37.5 18.5
Ligand B-chain 7.2 45.6 25
Wilson B-factor (Å2) 18.3 30 21.8
Protein Data Bank code 3ZR7 3ZRA 3ZRB
a Rpim h((1/(N 1))1/2iIi(h) I(h))/hiIi(h), where I is the observed intensity, and I is the average intensity of multiple observations from symmetry-related re-
flections. It is an indicator of the precision of the final merged and averaged dataset.
b Rfree was determined using 5% of the data.
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glucocorticoid activity. H-bond networks between ligands
(normally 11-OH groups in steroids) and Asn564 and from
Asn564 to Glu748 in the loop between helix-11 and helix-12 also
appear crucial for mediating a full agonistic response in gluco-
corticoid receptor (34). This interaction appears less important
for progestagenic activity as demonstrated by the lack of any
interaction between the endogenous ligand progesterone and
Asn719 in PR (13).
Despite the obvious differences betweenOrgA and norethin-
drone, OrgA is generally well tolerated within the same binding
pocket as the steroid (Fig. 5, A and B) with just the need for a
very small number of side chains to move a short distance as
shown in Fig. 6A. Fig. 6A also shows the pyrazole ring of OrgA
reaching into the pocket occupied by 17 groups from steroids
such as the ethinyl group of norethindrone (13). OrgA also
makes use of the space normally filled by 13-methyl groups in
classic progestagenic steroids with one of the sulfonamide
carbonyl oxygens oriented in close proximity and direction
to the hydroxyl oxygen on the 17 position of norethin-
drone. The sulfonamide carbonyl actually overlays closely
with the carbonyl oxygen in the 17-acetyl group of proges-
terone with one the methyl group in the acetyl overlaying
with one of the methyl substituents on the pyrazole of OrgA
(data not shown). Fig. 7A shows an overlay OrgA from mon-
omer A and monomer B demonstrating that no significant
difference appears to exist between the two monomers in
terms of ligand binding.
Clash with Met909 as a Contributing Factor to Partial Ago-
nism of OrgA—OrgA is a PR agonist but shows reduced efficacy
(60%) compared with norethindrone and progesterone (Fig. 1).
It has previously been shown that clashes between ligands and
Met909 in helix-12 of PR are a key determinant for reduced
agonistic activity in steroidal PR antagonists and partial ago-
nists (21). OrgA lacks an obvious structural mimic of the di-
methylaniline of RU486, or any of the other bulky 11 groups
common to PR antagonists of SPRMs (2). We did consider the
possibility that either the isoxazole end of the ligand or more
likely the pyrazole end might be oriented to overlay with the
11-substituent of RU486, but comparison of PR LBDs bound
to both ligands demonstrates that this is not case as can be seen
in Fig. 2B. However, despite the lack of the classic bulky side
chain, OrgA does still impede the agonist position of Met909 as
determined by its position bound to norethindrone, resulting in
the residue having to adopt a modified orientation. As can be
seen in Fig. 8A, the methylene linker between the phenyl ring
and the sulfonamide nitrogen in OrgA is only 2.3 Å from the
terminal carbon in the side chain ofMet909 from the previously
described full agonist conformation. This may be sufficient to
partially disrupt the ideal agonistic packing of helix-12 and
result in the reduced agonistic efficacy of OrgA (60%) com-
pared with the reference steroids progesterone and norethin-
drone. The fact that the clashwithMet909 ismade by part of the
central scaffold of the ligand might explain why of the nearly
1000 compounds tested in this series, none have been identified
as full PR agonists. The clash is not as significant as the clash
between Met909 and RU486, shown in Fig. 8C, in line with the
observation that OrgA is a partial agonist and not a full
antagonist.
Soaking Experiments Resulted in Complete Exchange of OrgA
by OrgB—To generate co-crystals of OrgB bound to PR, we
have taken PR LBD crystals bound toOrgA and soaked inOrgB
as described in earlier experiments (21). To be sure complete
exchange has occurred, it was important to carefully analyze
the electron density defining the position of the ligand to ensure
that it is only compatible with the soaked ligand. OrgB has a
disubstituted pyridine replacing the dimethylisoxazole of
OrgA, with the larger ring system of the pyridine resulting in a
different orientation of the attachments than we would expect
to see if the isoxazole was still in place. Next, the pyrazole of
OrgA has three substituents (two methyl groups and a chlo-
rine), but the electron density (as shown in Fig. 3, C and D)
indicates a ring with two substituents at this end of the struc-
ture compatible with the dimethylisoxazole in OrgB. Finally,
OrgB has an additional methyl group between the biaryl and
sulfonamide ends of its structure, which can be seen in the
electron density of the ligand in monomer B most clearly but
also in monomer A at lower  levels. These observations
together indicate that OrgB has completely displaced OrgA in
the crystals.
Structure of PR LBD Dimer Complexed to OrgB—The suc-
cessful soaking of OrgB into the OrgA co-expressed PR LBD
x-ray structures did not result in any significant change in the
structure of the receptor, despite the fact that OrgB is a full
FIGURE 3. Shown are the 2Fo DFc OMIT electron density maps around
the ligand and Trp755 in monomers A and B for each of the three com-
plexes shown at 1. 0. Trp755 is included as three-dimensional reference to
demonstrate that each of the ligands is shown in a comparable orientation. A
ismonomer A from the PR-OrgA complex, and B ismonomer B from the same
complex. C is monomer A from the PR-OrgB complex, and D is monomer B
from the same complex. Trp755 is shown in a dual conformation for this mon-
omer as indicated by the electron density map. E is monomer A from the
PR-OrgC complex, and F is monomer B from the same complex. Images were
generated using PyMOL. The ligand in monomer B is OrgC indicating a suc-
cessful exchange, but the electron density indicates that monomer A still
contains OrgA, indicating that exchange did not occur in this monomer.
Agonism and Antagonism in the Progesterone Receptor
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antagonist and OrgA is a partial agonist. As discussed in previ-
ously (21), it is likely that the receptor exists in equilibrium
between agonistic and antagonistic states with ligands at least
partly driving that balance. Therefore, although the agonistic
conformation of the receptor will not be the lowest energy con-
formation when bound to OrgB, it does remain a thermody-
namically accessible conformation, even if only present at low
concentrations. A number of clashes between OrgB and the
receptor are present in this structure. These include a clash
between the fluorine from the ligand with Val760, a clash with
the backbone oxygen of Leu715, and a final clash with Met756.
This is in contrast to the OrgA structure, which includes only a
moderate clash with Cys891, indicating that OrgA is better tol-
erated in the agonistic form of PR than OrgB. Physiologically it
is likely that these clashes are relieved as helix-12 is displaced on
binding of OrgB with the receptor adopting its antagonist
conformation.
Comparison of Binding Mode of OrgA Compared with OrgB—
As for OrgA, OrgB makes a direct H-bond to Asn719 via the
FIGURE 4.Overviewof the bindingmodes of norethindrone (A), RU486 (B), OrgA (C), andOrgB (D). The three key H-bonding residues, Asn719, Gln725, and
Arg766 are shown, alongwithwatermolecules directly H-bonding to ligands. The remainder of the protein is hidden for clarity. The norethindrone-PR complex
is fromProteinDataBank code1SQN (20), and theRU486-PRcomplex is also available in theProteinDataBank, code1W8Y (21). Protein residues are shownwith
carbons in orange, and ligands are shown with carbons in green. All structures have been energy-minimized using Yasara (see Ref. 33), and images were
generated using PyMOL.
FIGURE 5. A, norethindrone is shown as stickswith the binding pocket of the
PR-norethindrone complex shown as a surface. B, PR-OrgA complex overlaid
with PR-norethindrone complex using theMotif function in Yasara (33). OrgA
is shown in stick format with the binding pocket of the PR-norethindrone
complex shown as a surface for comparison. C, PR-OrgB complex overlaid
with PR-norethindrone complex using theMotif function in Yasara (33). OrgB
is shown in stick format with the binding pocket of the PR-norethindrone
complex shown as a surface for comparison. Surface and imageswere gener-
ated in PyMOL.
FIGURE 6. A, overlaid binding pockets of PR-norethindrone complex (carbons
colored green) with PR-OrgA complex (carbons colored magenta). Residues
with the largest deviation in position between these two complexes are
shown as sticks and labeled, and the remaining residues around the binding
pocket are shownas lines.B,asper imageA, but PR-OrgAcomplex replacedby
PR-OrgB complex (carbons colored blue). Images were generated in PyMOL.
Agonism and Antagonism in the Progesterone Receptor
OCTOBER 7, 2011•VOLUME 286•NUMBER 40 JOURNAL OF BIOLOGICAL CHEMISTRY 35083
 at RA
D
BO
U
D
 U
N
IV
ERSITEIT N
IJM
EG
EN
 on M
arch 6, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
nitrogen of its sulfonamide group shown in Fig. 3D. Unlike for
OrgA, the conserved water molecule between Gln725 and
Arg766 is not present. Instead, the pyridine nitrogen of OrgB
makes a direct H-bond to Gln725, an interaction only possible
due to the movement of the residue in this structure compared
with PR-OrgA, PR-RU486, and PR-norethindrone structures
described earlier. Despite this interesting difference, the most
striking change between the binding of OrgA and OrgB was
observed around their sulfonamides and the hetero-aryl groups
attached to them.
As outlined earlier, the pyrazole group of OrgA is directed
toward the so-called 17 pocket, but for OrgB, the isoxazole
equivalent to this group is directed in a distinctly different
direction toward Trp755. Despite this significant difference, the
two observed binding modes for the series share a number of
key characteristics. Both are able to mimic the 3-keto group of
steroids, and they both make use of the hydrophobic region
around the steroidal position 13, make a direct H-bond to
Asn719 via the nitrogen of the sulfonamide group, and position
a carbonyl from the sulfonamide in the same region as the oxy-
gen in either of the two different 17 groups of progesterone
and norethindrone.
Fig. 7B shows the overlay of OrgB from monomer-A and
monomer-B, demonstrating that they are practically identi-
cal. Despite this, their bindingmode, directed toward Trp755,
has a different effect depending on the monomer. Specifi-
cally, in monomer-B, Trp755 shows a double conformation,
presumably as a result of the close proximity of the ligand.
This “flipping” of Trp755 has been observed previously (30)
but does not appear to correlate with any change in agonism
or antagonism.
Clash with Met909 as a Contributing Factor to Full Antago-
nism of OrgB—Despite adopting a different binding mode to
OrgA, OrgB still clashes with Met909 in the classic agonistic
position, but now via one of the methyl groups on the isoxa-
zole ring as shown in Fig. 8B. In fact, compared with a partial
agonist like OrgA, the clash between OrgB and Met909
appears slightly more significant and likely to be a contrib-
uting factor to the full antagonism seen in this series. The
clash is still not as significant as the clash between Met909
and RU486, and it is therefore likely that there are other
additional factors that render OrgB as a full antagonist com-
pared with the partial agonist OrgA.
Disrupted InteractionbetweenHelix-3andHelix-5asaContrib-
uting Factor in the Reduced Agonism of OrgA and OrgB—Ago-
nism in steroid receptors is dependent, at least in part, on the
stabilization by interactions between helices 3 and 5. This has
most clearly been shown for the mineralocorticoid receptor
(35–39), a very close relation of PR. Ligand-mediated (and often
water-bridged) interactions between Gln725 in helix-3 and
Arg766 in helix-5 are key components in the interaction
between these helices. As discussed previously, and shown in
Fig. 4A, agonistic steroids such as norethindrone participate in
directly mediating an H-bond network between these two res-
idues via their 3-keto groups. This appears to result in the bend-
ing of helix-3, and the correct orientation of the charge-clamp
residue Lys734. Lys734 in helix-3 and Glu911 in helix-12 are in
part responsible for the binding of co-modulating proteins
FIGURE 7. A, overlay of OrgA from monomer A (shown with carbons colored
green) and OrgA from monomer B (shown with carbons colored cyan) from
x-ray structure 1. B, overlay of OrgB from monomer A (shown with carbons
coloredgreen) andOrgA frommonomer B (shownwith carbons colored cyan)
from x-ray structure 2. C, overlay of OrgA from monomer A (shown with car-
bons colored green) andOrgC frommonomer B (shownwith carbons colored
cyan) from x-ray structure 3. Images were generated in PyMOL.
FIGURE 8. A, overlay of PR-norethindrone complex (carbons colored green)
with PR-OrgA complex (carbons colored cyan). Met909 from the PR-norethin-
drone complex is shown along with the ligands. Helix-12 is shown as a red
schematic. Distance between the -carbon in Met909 and the nearest heavy
atom in OrgA is shown. B, as per image A, but PR-OrgA complex replaced by
PR-OrgB. C, as per image A, but PR-OrgA complex replaced by RU486. Mea-
surements were made and images generated in PyMOL.
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by capping either end of classic LXXLL-binding helices pres-
ent in co-modulators. Neither OrgA nor OrgB faithfully
reproduced the important H-bond network between Gln725
and Arg766, which may certainly contribute to their reduced
agonistic efficacy compared with full agonists. For the full
antagonist OrgB, no interaction between Gln725 and Arg766
is retained, but the partial agonist OrgA does retain the often
conserved water molecule, allowing for a partial retention of
the network. It may be possible that this difference contrib-
utes to the difference we see in the function of OrgA com-
pared with OrgB.
Molecular Basis for Differences in Binding Modes—Under-
standing the basis for the switch in binding mode, which
appears to result in a switch from partial agonism to full antag-
onism, was our next goal. An obvious difference betweenOrgA
and the two full antagonists is the presence of an extra stereo
center in the latter, due to the presence of an additional methyl
group between the biaryl and sulfonamide substructures. The
bindingmode of OrgB orients this methyl group toward Leu715
in an area of the pocket well able to tolerate its presence. How-
ever, examination of the binding mode of OrgA shows that the
methyl group of OrgB would not be tolerated in this binding
mode, most likely clashing with Cys891, Trp755, and Met756.
Although Trp755 could adopt a second position that would
relieve this clash, the Cys891 clash would remain unresolved.
We therefore conclude that the presence of this methyl group
results in the compound series adopting a second bindingmode
that is only compatible with a displacement of helix-12 and
therefore induce full antagonism.
Antagonism of OrgD Confirms Importance of Methyl Group
in Determining Function—OrgD is identical to the agonist
OrgA except for the addition of a methyl group branched from
the carbon atom next to the nitrogen atom in the sulfonamide
substructure. PR agonism and antagonism were measured for
OrgD (Fig. 1) following the earlier described procedure that
clearly identifies this compound as a PR antagonist. This exper-
iment confirms the importance of the methyl group in differ-
entiating between PR agonism and antagonism and therefore
supports the structural biology conclusion that this methyl
induces a different binding mode for the series that results in a
switch from agonism to antagonism.
Structure of PR LBD Dimer Complexed to OrgA and OrgC—
Following the same procedure described for OrgB, we
attempted to soak OrgC into PR LBD co-crystallized with
OrgA. Analysis of the resulting electron density indicated
clearly that OrgC had fully replaced OrgA in monomer-B as
hoped but that OrgA was still present in monomer-A. In our
previous study, RU486 was able to exchange fully with nore-
thindrone in monomer-B but did not replace the co-expressed
ligand in monomer-A (21). It has previously been postulated
that this difference in success is a result of monomer-B being
more open than monomer-A (21).
OrgA in monomer-A of this third x-ray structure remains in
the same orientation that we have seen earlier for the binding of
OrgA in PR. OrgC, however, adopts the binding orientation of
OrgB as shown in Fig. 3,E and F. The overlay of the ligands from
the two monomers, demonstrating the divergent binding
modes of compounds from the same series bound to the same
dimer, is shown in Fig. 7C. As themonomer with the successful
soaking of the full antagonist OrgC adopts the same binding
mode as the full antagonist OrgB, we presume that they also
share the mechanism for their antagonism. Interestingly,
although we see a flip of Trp755 in monomer-B bound to OrgB,
we do not see the same flipping of Trp755 in the samemonomer
when bound to OrgC.
Conclusion—We describe here three new PR LBD x-ray
structures bound to three structurally related but pharmaco-
logically different compounds, including the first reported
structures of PR bound to nonsteroidal antagonists. The ago-
nist and antagonist compounds display distinct bindingmodes,
with the antagonists displaying a more profound clash with
Met909 from helix-12 than a partial agonist from the same
series. The clash with Met909 reinforces the key role of this
residue in the switch between agonism and antagonism of PR
ligands as previously shown for 11-steroids (21) and other
nonsteroidal antagonists. The ability to tolerate two distinct
bindingmodes is further evidence of the plasticity of the steroid
receptor binding pocket.
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